Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Talfirastide by Constant Therapeutics for Ischemic Stroke: Likelihood of Approval
Talfirastide is under clinical development by Constant Therapeutics and currently in Phase II for Ischemic Stroke. According to GlobalData, Phase...